Skip to Main Content

The World Health Organization added a Regeneron Pharmaceuticals medication to its list of recommended treatments for Covid-19, and at the same time, joined Unitaid in criticizing the company’s pricing and distribution of the drug globally.

As part of their message, the agencies also urged Regeneron to transfer technology used to make its monoclonal antibody to other manufacturers so that lower-cost biosimilar versions could be made more quickly for low and middle-income nations. They also directed the message at Roche (RHHBY), which struck a deal with Regeneron to make the treatment for distribution outside the U.S.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment